The U.S. Food and Drug Administration expanded the indication of Supernus Pharmaceuticals Inc.’s Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older.

Researchers at Emory investigated the use of an FDA-approved ADHD medication on patients with mild Alzheimer’s symptoms and found it appeared to reduce levels of tau.

Shares of Supernus Pharmaceuticals climbed in trading on April 5 after the U.S. Food and Drug Administration’s April 2 approval of the company’s non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age.

One year after submitting a New Drug Application for Azstarys, the U.S. Food and Drug Administration approved KemPharm’s novel ADHD drug for use in patients 6 years and older.

Supernus Pharmaceuticals Inc.’s experimental drug for attention deficit hyperactivity disorder (ADHD) met the main goal of a late-stage study in adults.

ADHD (attention-deficit/hyperactivity disorder) may be more common in elite athletes, a new research review suggests.

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the launch of the generic equivalent to INTUNIV® (guanfacine) 1 mg, 2 mg, 3 mg, and 4 mg, in the United States. […]